Immunotherapy with immune checkpoint inhibitors targeting programmed death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) has great applicability in treating various cancers, including GC, melanoma, renal cell carcinoma, and lung cancer [4–9]. Here, CD274 is linked to cancer.